Cardiology Market Forecast - Table Of Contents
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Cardiology Market Forecast - Table Of Contents as PDF for free.
More details
- Words: 500
- Pages: 4
Therapeutic Market Outlooks
Lipid Modulating Agents Publication Date: August 2007 Table of Contents Disease Etiology................................................................... 6 Primary Dyslipidemia ...................................................... 6 Secondary Dyslipidemia .................................................. 6 Epidemiology & Patient Population Estimates........................... 7 Theoretical Patient Population.......................................... 7 Addressable Patient Population ........................................ 7 Treated Patient Population .............................................. 8 Drivers of Growth ..................................................... 8 Availability of Generics......................................... 8 Access for Elderly................................................ 8 Public Awareness ................................................ 8 New Guidelines................................................... 8 Dyslipidemia Patient Population Model .............................. 9 U.S. Statins Market Model, 2004-2013 .................................. 10 Disease & Market Definitions ......................................... 10 Forecasting Methodology............................................... 10 Market Segmentation.................................................... 10 Market Revenue Forecasts............................................. 11 AVOS Physician Panel Results .............................................. 15 Physician Treatment Patterns......................................... 15 Patient Compliance ....................................................... 16 Drivers of Non-Compliance ...................................... 16 Asymptomatic Prevention .................................. 16 Cost ................................................................ 16 Natural Treatment ............................................ 16 Side Effects...................................................... 16 Lack of Education ............................................. 16 Physician Product Selection Criteria ................................ 17 Insurance Coverage ................................................ 17 Sample Availability.................................................. 17 Efficacy ................................................................. 17
www.avoslifesciences.com
[email protected]
Marketing Efforts .................................................... 17 Physician Product Ratings & Forecasts of Future Market Trends ........................................................................ 18 Market Overview ................................................................ 20 Leading Products.......................................................... 20 Market History ............................................................. 20 Current Market Environment.......................................... 21 Future OTC Switch Unlikely ........................................... 22 Product Profiles Lipitor ......................................................................... 23 U.S. Perspective ..................................................... 23 Worldwide Perspective ............................................ 24 AVOS Physician Panel Discussions ............................ 24 Zetia/Vytorin................................................................ 25 U.S. Perspective ..................................................... 25 Worldwide Perspective ............................................ 26 AVOS Physician Panel Discussions ............................ 26 Product History ...................................................... 27 Crestor........................................................................ 28 U.S. Perspective ..................................................... 28 Worldwide Perspective ............................................ 29 AVOS Physician Panel Discussions ............................ 29 Crestor Safety Controversy ...................................... 30 Zocor .......................................................................... 31 U.S. Perspective ..................................................... 31 Worldwide Perspective ............................................ 32 AVOS Physician Panel Discussions ............................ 32 Pravachol .................................................................... 33 U.S. Perspective ..................................................... 33 Worldwide Perspective ............................................ 33 AVOS Physician Panel Discussions ............................ 34 Lescol/Lescol XL ........................................................... 35 U.S. Perspective ..................................................... 35 Worldwide Perspective ............................................ 35 AVOS Physician Panel Discussions ............................ 35 Tricor.......................................................................... 36 U.S. Perspective ..................................................... 37 www.avoslifesciences.com
[email protected]
Worldwide Perspective ............................................ 37 Product History ...................................................... 37 Patent Challenges and Reform ................................. 37 AVOS Physician Panel Discussions ............................ 37 Niaspan/Advicor ........................................................... 38 U.S. Perspective ..................................................... 38 Worldwide Perspective ............................................ 39 Product History ...................................................... 39 AVOS Physician Panel Discussions ............................ 39 Caduet ........................................................................ 40 U.S. Perspective ..................................................... 40 Worldwide Perspective ............................................ 41 AVOS Physician Panel Discussions ............................ 41 Atorvastatin ................................................................. 42 U.S. Perspective ..................................................... 42 Worldwide Perspective ............................................ 43 AVOS Physician Panel Discussions ............................ 43 MK-0524A/MK-0524B .................................................... 44 U.S. Perspective ..................................................... 44 Worldwide Perspective ............................................ 45 AVOS Physician Panel Discussions ............................ 45 Simcor ........................................................................ 46 U.S. Perspective ..................................................... 46 Worldwide Perspective ............................................ 46 AVOS Physician Panel Discussions ............................ 47 ABT-335/Crestor + ABT-335 .......................................... 48 U.S. Perspective ..................................................... 48 Worldwide Perspective ............................................ 49 AVOS Physician Panel Discussions ............................ 49 TAK-475...................................................................... 50 U.S. Perspective ..................................................... 50 Worldwide Perspective ............................................ 51 AVOS Physician Panel Discussions ............................ 51 Drugs in Development ........................................................ 52 R&D Overview ............................................................. 52 ACAT Inhibitors ...................................................... 52 Squalene Synthase Inhibitors ................................... 52 www.avoslifesciences.com
[email protected]
PPAR Agonists........................................................ 52 CETP Inhibitors ...................................................... 52 Assessment of R&D Success Rates ................................. 52 Products in the Pipeline................................................. 53 Phase III (11 Agents).............................................. 53 Phase II (11 Agents)............................................... 54
www.avoslifesciences.com
[email protected]
Lipid Modulating Agents Publication Date: August 2007 Table of Contents Disease Etiology................................................................... 6 Primary Dyslipidemia ...................................................... 6 Secondary Dyslipidemia .................................................. 6 Epidemiology & Patient Population Estimates........................... 7 Theoretical Patient Population.......................................... 7 Addressable Patient Population ........................................ 7 Treated Patient Population .............................................. 8 Drivers of Growth ..................................................... 8 Availability of Generics......................................... 8 Access for Elderly................................................ 8 Public Awareness ................................................ 8 New Guidelines................................................... 8 Dyslipidemia Patient Population Model .............................. 9 U.S. Statins Market Model, 2004-2013 .................................. 10 Disease & Market Definitions ......................................... 10 Forecasting Methodology............................................... 10 Market Segmentation.................................................... 10 Market Revenue Forecasts............................................. 11 AVOS Physician Panel Results .............................................. 15 Physician Treatment Patterns......................................... 15 Patient Compliance ....................................................... 16 Drivers of Non-Compliance ...................................... 16 Asymptomatic Prevention .................................. 16 Cost ................................................................ 16 Natural Treatment ............................................ 16 Side Effects...................................................... 16 Lack of Education ............................................. 16 Physician Product Selection Criteria ................................ 17 Insurance Coverage ................................................ 17 Sample Availability.................................................. 17 Efficacy ................................................................. 17
www.avoslifesciences.com
[email protected]
Marketing Efforts .................................................... 17 Physician Product Ratings & Forecasts of Future Market Trends ........................................................................ 18 Market Overview ................................................................ 20 Leading Products.......................................................... 20 Market History ............................................................. 20 Current Market Environment.......................................... 21 Future OTC Switch Unlikely ........................................... 22 Product Profiles Lipitor ......................................................................... 23 U.S. Perspective ..................................................... 23 Worldwide Perspective ............................................ 24 AVOS Physician Panel Discussions ............................ 24 Zetia/Vytorin................................................................ 25 U.S. Perspective ..................................................... 25 Worldwide Perspective ............................................ 26 AVOS Physician Panel Discussions ............................ 26 Product History ...................................................... 27 Crestor........................................................................ 28 U.S. Perspective ..................................................... 28 Worldwide Perspective ............................................ 29 AVOS Physician Panel Discussions ............................ 29 Crestor Safety Controversy ...................................... 30 Zocor .......................................................................... 31 U.S. Perspective ..................................................... 31 Worldwide Perspective ............................................ 32 AVOS Physician Panel Discussions ............................ 32 Pravachol .................................................................... 33 U.S. Perspective ..................................................... 33 Worldwide Perspective ............................................ 33 AVOS Physician Panel Discussions ............................ 34 Lescol/Lescol XL ........................................................... 35 U.S. Perspective ..................................................... 35 Worldwide Perspective ............................................ 35 AVOS Physician Panel Discussions ............................ 35 Tricor.......................................................................... 36 U.S. Perspective ..................................................... 37 www.avoslifesciences.com
[email protected]
Worldwide Perspective ............................................ 37 Product History ...................................................... 37 Patent Challenges and Reform ................................. 37 AVOS Physician Panel Discussions ............................ 37 Niaspan/Advicor ........................................................... 38 U.S. Perspective ..................................................... 38 Worldwide Perspective ............................................ 39 Product History ...................................................... 39 AVOS Physician Panel Discussions ............................ 39 Caduet ........................................................................ 40 U.S. Perspective ..................................................... 40 Worldwide Perspective ............................................ 41 AVOS Physician Panel Discussions ............................ 41 Atorvastatin ................................................................. 42 U.S. Perspective ..................................................... 42 Worldwide Perspective ............................................ 43 AVOS Physician Panel Discussions ............................ 43 MK-0524A/MK-0524B .................................................... 44 U.S. Perspective ..................................................... 44 Worldwide Perspective ............................................ 45 AVOS Physician Panel Discussions ............................ 45 Simcor ........................................................................ 46 U.S. Perspective ..................................................... 46 Worldwide Perspective ............................................ 46 AVOS Physician Panel Discussions ............................ 47 ABT-335/Crestor + ABT-335 .......................................... 48 U.S. Perspective ..................................................... 48 Worldwide Perspective ............................................ 49 AVOS Physician Panel Discussions ............................ 49 TAK-475...................................................................... 50 U.S. Perspective ..................................................... 50 Worldwide Perspective ............................................ 51 AVOS Physician Panel Discussions ............................ 51 Drugs in Development ........................................................ 52 R&D Overview ............................................................. 52 ACAT Inhibitors ...................................................... 52 Squalene Synthase Inhibitors ................................... 52 www.avoslifesciences.com
[email protected]
PPAR Agonists........................................................ 52 CETP Inhibitors ...................................................... 52 Assessment of R&D Success Rates ................................. 52 Products in the Pipeline................................................. 53 Phase III (11 Agents).............................................. 53 Phase II (11 Agents)............................................... 54
www.avoslifesciences.com
[email protected]
Related Documents
Cardiology Market Forecast - Table Of Contents
October 2019 4
Metabolic Market Forecast - Table Of Contents
October 2019 3
Market Appraisal Table Of Contents
November 2019 4
Table Of Contents
June 2020 10
Table Of Contents
June 2020 8